BAB 5 KESIMPULAN DAN SARAN
5.2. Saran
Masih dibutuhkan penelitian baru yang mampu menjelaskan korelasi parameter hemostasis terhadap tumor marker berdasarkan jenis kelamin, usia, jenis histologi sel dan jenis kemoterapi.
DAFTAR PUSTAKA
A. A. Ponomaryova et al, 2011 Molecular Genetic Markers in Diagnosis of Lung Cancer, Institute of Oncology, Siberian Branch, Russian Academy of Medical Sciences, Tomsk, 634001 Russia, ISSN 0026_8933, Molecular Biology, 2011, Vol. 45, No. 2, pp. 175–189.
A. Falanga et al, 2013, Coagulation and cancer: biological and clinical aspects, Jurnal of Thrombosis and Haemostasis,II,Itali, 2013, 223-233.
Andrew, D Blann, et al, 2011, Arterial and Venous Thrombosis in Cancer Patients, Cardiology Research and Practice, 2ulation and Anticoagulation.
Annie Young et al, 2012, Thrombosis and cancer, Department of Haematology, University Hospital, Clifford Bridge Road, Coventry CV2 2DX, UK.
NATURE REVIEWS | Clinical Oncology, Volume 9 | August 2012.
Anthony Letai and David J Kuter, 1999, Cancer, Coagulation and anticoagulation, Hematology Oncology Departement, Boston, USA.
Berna Komurcuoglu et al, 2011, prognostic value of plasma D-dimer levels in lung carcinoma, Tumori 97, Turki, 2011, 743-748
Bo Jin et al, 2010, The Value of Tumor Markers in Evaluating Chemotherapy Response and Prognosis in Chinese Patients with Advanced Non-Small Cell Lung Cancer, Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China, Chemotherapy 2010;56:417–42
Buku ajar Penyakit Dalam FK UI, 2006, Dasar-dasar Hemostasis dan Thrombosis pada kanker, Jakarta.
Dangfan Yu et al, 2013, Prognostic Value of Tumor Markers, NSE, CA125 and SCC,in Operable NSCLC Patients Department of Nuclear Medicine, Zhejiang Provincial Corps Hospital, Chinese People‟s ArmedPolice Force, Jiaxing 314000, China Int. J. Mol. Sci.
D. Ferrigno et al, 1994, Serum tumour markers in lung cancer: history, biology and clinical applications Dept of Nuclear Medicine, S. Croce General Hospital, Cuneo, Italy. Eur Respir J, 1994, 7, 186–197,
Ebru Unsal et al, 2003, Prognostic pnificance of hemostatic parameters in patients with lung cancer,ELSEVIER, Turki 2003.
Faruk Tas et al, 2013, Clinical and prognostic pnificance of coagulation assays in lung cancer, Institute of Oncology, University of Istanbul, Istanbul, Turkey, Elsevier Ltd., Respiratory Medicine, 2013, 107, 451e457
Gerald A. Soff, 2013, Pathophysiology and management of thrombosis in cancer:150 years of progress, J Thromb Thrombolysis (2013) 35:346–351 DOI 10.1007/s11239-013-0897-9
IASLC/ATS/ERS, 2011, Internasional Multidisciplinary Classfisication of Lung Adenocarcinoma, Journal of Thoracic Oncology, IASLC.
Isabel Dos Santos Silva, 2010, Circulating Levels of Coagulation and Inflammatin markers and cancer risks: individual participant analysis af data from three long-terms cohort, Departement of Epidemiology and Population health,
London school of Hygiene and Tropical Medicine, London, International Journal of Epidemiology, London.
Jung zao et al, 2012, Tumor response and survival in patients with advanced non-small-cell lung cancer: the predictive value of chemotherapy-induced changes in fibrinogen, Department of Medical Oncology, The First Hospital, China Medical University, Shenyang, China, Zhao et al. BMC Cancer 2012, 12:330. http://www.biomedcentral.com 1471-2407/12/330
Kementrian Kesehatan Republik Indonesia, 2011, Pedoman Interpretasi Data Klinik, Jakarta.
Kostas D.Hatzakis et al, 2002, Prognostic Value of Serum Tumor Markers in Patients with Lung Cancer, Departemens of Pneumonology and Nuclear Medicine, University of Crete Medical School, heraklion, Greece, Repiration; Jan/Feb 2002;69; Proquest
Ljiljana Vasic, 2007, A Role of Cyfra 21-1 Among Tumor Markers for Non-Small-Cell Lung Cancer Acta Fac Med Naiss 2007; 24 (2): 65-69
Michael. E. Bromberg et al, 1999, Cancer and Blood Coaguloation: Molecular Aspect, The Cancer Journal From Scientific American.
M. Roselli et al, 2014, Clinical models and biochemical predictors of VTE in lung cancer, Department of Systems Medicine, Medical Oncology, Tor Vergata Clinical Center, University of Rome “Tor Vergata”, Viale Oxford 81, 00133 Rome, Italy, Cancer Metastasis Rev, 2014, 33:771–789 DOI 10.1007/s10555-014-9500-x
Paolo Prandoni et al, 2005, Cancer and venous thromboembolism, Department of Medical and Surgical Sciences, Second Chair of Internal Medicine, University of Padua, Padua, ItalyLancet Oncol 2005; 6: 401–10
Perhimpunan Dokter Paru Indonesia (PDPI), 2011, Kanker paru, Pedoman Diagnosis dan penatalaksanaan di Indonesia, Perhimpunan Dokter Paru Indonesia, Jakarta, 2011.
Peter Oppelt et al, 2015, Approach to chemotherapy-associated thrombosis, Case Western Reserve University, Cleveland, OH 44106, USA, Vascular Medicine 2015, Vol. 20(2) 153–161
Petra Stieber et al, 2006, National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Lung Cancer NACB: Practice Guidelines And Recommendations For Use Of Tumor Markers In The Clinic Lung Cancer (Section 3P, NACB.2006
P.P. Mumbarkar et al, 2006, Significance of Tumor Markers In Lung Cancer Department of Biochemistry, Tata Memorial Hospital, Parel, Mumbai Indian Journal of Clinical Biochemistry, 2006, 21 (1) 173-176
R Molina et al, 2003, Tumor Markers (CEA, CA 125, CYFRA 21-1,SCC and NSE) in patients with Non-Small Cell Lung Cancer as an Aid in Histological Diagnostic and Prognosis, Comparison with the Main Clinical and Pathological Prognostic Factors, Laboratory of Clinical Biochemistry,Unit for Cancer Research, Hospital Clinic and Unit of Epidemiology and Cancer
Registry,Hospital I Duran I Reynals, Barcelona, Tumor Biology 2003:24;24;209-218.
Salah Abbasi and Ahmed Badheed, Prognostic Factors in advanced Non-Small-Cell Lung Cancer patients: Patient Characteristic and Type of Chemoterapy, Clinical Oncology Department,King Hussien Center, Al-jubeiha, Amman 11941,Jordan
Shaker A. Mousaet al, 2004, Angiogenesis Inhibitors: Current & Future Directions, Albany College of Pharmacy & Pharmaceutical Research Institute (PRI) at Albany, Albany, NY and 1Cornell University, Ithaca, NY, USA Current Pharmaceutical Depn, 2004, 10, 1-9
Slavica Kvolik, 2010, An overview of coagulation disorders in cancer patients, Department of Anesthesiology and ICU, University Hospital Osijek, J.
Huttlera Osijek, Croatia, Surgical Oncology.
U.S. Cancer Statistics-working Group, 2012, United State Cancer Statistics 1999-2012, incidence and mortality web-based Report, Atalanta, U.S. Deparment of Health and Human Services, Center of diseases Control and Prevention, and National Cancer Institute, 2015. Available at: www.cdc.gov/uscs. . Yuan liu et al, 2011, Tissue Factor-activated Coagulation Cascade in the tumor
Microenvironment in Critical for tumor Progression and an effective Target for Therapy, Therapeutic, Targets and Chemical Biology, North Carolina, 2011.
LAMPIRAN 1
LEMBARAN PEMERIKSAAN PENELITIAN
Nama :
Umur : Tahun
Tempat/ Tanggal Lahir :
Alamat :
Pekerjaan :
No.Telepon :
Jenis Kelamin : 1. Laki-laki
2. Perempuan Keluhan respiratori yang pernah dialami :
1. Batuk 2. Sesak Napas 3. Nyeri
4. Batuk darah 5. Lainnya Riwayat Merokok:
1. Merokok 2. Tidak Merokok
Riwayat penyakit paru sebelumnya :
Hasil Foto toraks PA/Lateral : Hasil CT Scan Toraks (bila ada) : Hasil Bronkoskopi (bila ada) :
Hasil Citologi Jaringan :
Hasil Histopatologi Jaringan :
Diagnosa Akhir :
LAMPIRAN 2
LEMBAR PENJELASAN KEPADA CALON SUBJEK PENELITIAN
Selamat pagi/siang Bapak/Ibu, saya dr. Ganda M. Leonard Samosir, PPDS Departemen Pulmonologi dan Kedokteran Respirasi, saat ini sedang melakukan penelitian yang berjudul “Korelasi Faal Hemostasis dengan Tumor Marker Pada Pasien Kanker Paru Bukan Sel Kecil dengan Kemoterapi”, Penelitian ini bertujuan untuk melihat hubungan antara faal hemostasis dan tumer marker bapak/ibu dalam pengaruhnya terhadap kemoterapi, yang nantikan akan digunakan dalam menilai prognosis dari penyakit bapak/ibu.
Bapak/ibu yang bersedia mengikuti penelitian ini nantinya akan dilakukan pemeriksaan darah setiap sebelum memulai kemoterapi dan setelah menjalani kemoterapi 2 siklus dan kemoterapi 4/6 siklus.
Kami sangat mengharapkan keikutsertaan bapak/ibu dalam penelitian ini, semua data dan hasil penelitian ini bersifat rahasia, tidak diketahui orang lain.
Apabila berkeberatan, bapak/ibu bebas untuk menolak mengikuti penelitian ini. Jika sudah mengerti dan bersedia mengikuti penelitian ini. Bapak/ibu dapat mengisi lembar persetujuan.
Bila terjadi hal-halyang tidak diinginkan selama penelitian berlangsung, yang disebabkan oleh perlakuan pada penelitian ini, bapak/ibu dapat menghubungi saya:
Nama : dr. Ganda M. Leonard Samosir
Alamat Kantor : Departemen pulmonologi dan Ilmu Kedokteran Respirasi FK USU-RS HAM,Jln BUnga Lau No.17. Telp. 061-8365915 Alamat Rumah : Jalan Sedap Malam 16 no 10 medan selayang. Medan
No telp.082165516380
Demikian penjelasan ini saya sampaikan, kiranya hasil dari penelitian ini dapat bermanfaat bagi kita semua.
Medan, Februari 2016 Peneliti
(dr. Ganda M.Leonard Samosir)
LAMPIRAN 3
LEMBAR PERSETUJUAN IKUT SERTA DALAM PENELITIAN Saya yang bertanda tangan dibawah ini:
Nama :
Umur : Tahun
Jenis Kelamin :
Alamat :
Menyatakan telah mendapatkan keterangan dan penjelasan mengenai materi penelitian, prosedur tindakan dan manfaat penelitian yang berjudul “Korelasi Faal
Hemostasis dan Tumor Marker pada Kanker Paru Bukan Sel Kecil dengan Kemoterapi”. Ringkasan keterangan mengenai penelitian ini telah diberikan kepada saya. Saya mengetahhui dan mempunyai kebebasan untuk ikut serta dalam penelitian
ini dan berhak sewaktu-waktu mengundurkan diri selama penelitian berlangsung.
Saya setuju secara sukarelaikut serta dalam penelitian ini.
Medan, / / 2016
Mengetahui, Menyetujui
dr. Ganda M.Leonard Samosir Subjek Penelitian/saksi